Cargando…

Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728513/
http://dx.doi.org/10.1007/s40278-020-87245-5
_version_ 1783621288926904320
collection PubMed
description
format Online
Article
Text
id pubmed-7728513
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77285132020-12-11 Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report Reactions Weekly Case Report Springer International Publishing 2020-12-12 2020 /pmc/articles/PMC7728513/ http://dx.doi.org/10.1007/s40278-020-87245-5 Text en © Springer International Publishing AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
title Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
title_full Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
title_fullStr Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
title_full_unstemmed Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
title_short Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
title_sort brentuximab-vedotin/nivolumab: sars-cov-2 infection: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728513/
http://dx.doi.org/10.1007/s40278-020-87245-5